PDO MAX INC, a medical device provider for medical aesthetic needs in the United States and Canadian markets, has received 510(k) approval from the US Food and Drug Administration (FDA) for its brand of PDO (polydioxanone) absorbable threads in cannula, it was reported on Friday.
PDO threads are utilised in aesthetic medicine and are a sterile, biodegradable, monofilament synthetic composed polymer. The approval is for both the PDO threads and cannula integrated into one device, unlike many of the other providers in the market.
Juliana Ucchino, vice president of Operations for PDO Max Inc, said, 'We are dedicated to bringing our aesthetic medical professionals, true peace of mind with our FDA cleared PDO threads. PDO MAX threads, used alone, or in addition to the provider's preferred injectable product, greatly add to the ability of our medical professionals to deliver nonsurgical, minimally invasive total facial aesthetics solutions.'
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Arbele's ARB1002 receives US FDA Orphan Drug Designation
Compass Pathways wins FDA IND acceptance for COMP360 PTSD trial
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
GSK wins European Commission approval for Shingrix prefilled syringe
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
Oculis secures FDA Breakthrough Therapy Designation for Privosegtor in optic neuritis
Esco Aster partners with Shine-On Biomedical for HLA-G targeting exosome drug delivery platform
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes